FDA Opens First Grant Funding Application Period for FY2022 for Animal Drugs for Minor Uses and Minor Species
Sponsors with Designated MUMS animal drugs who meet the eligibility requirements or their research partners are encouraged to apply.
May 28, 2021
The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development and approval or conditional approval of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species (MUMS).
The maximum individual award amount is $250,000 each, for up to two years for routine studies and up to three years for toxicology studies. Only animal drug sponsors with Designated MUMS animal drugs or their research partners are eligible to apply. Applicants must also meet other eligibility requirements.
To date, the MUMS grant program has provided more than $5.6 million in support of 63 studies. In December 2020, the FDA awarded a new grant to Cornell University for $137,063, to study the safety of a 10% eugenol solution as a sedative in clownfish. This month, the program awarded a total of $499,623 for the second year of two existing multi-year grants. The first recipient, Anivive Lifesciences, Inc. will use the grant award to continue a field study to determine the effectiveness of verdinexor for the treatment of lymphoma in dogs. The second recipient, Okava Pharmaceuticals, Inc., will continue an effectiveness study for OKV-1001 for adjunctive therapy for the treatment of newly diagnosed idiopathic (non-associative) immune-mediated hemolytic anemia (IMHA) in dogs. The first year of funding for these grants was awarded in May 2020.
The Minor Use and Minor Species Animal Health Act of 2004 (the MUMS Act) helps provide innovative ways to bring products to market for these small populations and is designed to help veterinary pharmaceutical companies and others overcome the financial roadblocks they face in providing animal drugs for a limited market. Before this legislation, veterinary pharmaceutical companies and others would rarely attempt to bring such drugs to market.
Grants awarded through the MUMS program support the FDA’s continuing mission to assure that safe and effective animal drugs are available for a wide range of species and conditions. MUMS grants have been awarded to support product development for a variety of indications, including the treatment and control of specific parasitic and bacterial diseases in various fish species, the treatment of particular cancers in dogs, and some uses for horses, pheasants, and goats.
This is Notice of Funding Opportunity (NOFO) Announcement Number PAR-21-179. The deadline to submit applications is July 30, 2021, through www.grants.gov or the NIH ASSIST system.
The complete NOFO is available at https://grants.nih.gov/grants/guide/pa-files/PAR-21-179.html.
Issued by FDA Center for Veterinary Medicine.
For questions, Contact CVM.